ZNTL analyst estimates

Zentalis (ZNTL) analyst ratings, the average price target and its range, and every firm's latest call.

ZNTL analyst ratings and price targets

DateFirmCallTarget
Nov 10, 2026WedbushWedbush Upgrades Zentalis Pharmaceuticals (ZNTL) to Outperform$6.00
Oct 5, 2026Leerink PartnersZentalis assumed at Outperform from Market Perform at Leerink$8.00
Aug 7, 2026Morgan StanleyZentalis price target raised to $5 from $4 at Morgan Stanley$5.00
May 22, 2026H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)$10.00
Apr 10, 2026GuggenheimZentalis price target raised to $10 from $6 at Guggenheim$10.00
Nov 11, 2025Leerink PartnersZentalis Pharmaceuticals (ZNTL) PT Lowered to $2 at Leerink Partners$2.00
Jun 18, 2024WedbushWedbush downgrades Zentalis to Underperform on unclear azeno path forward$4.00
Jun 18, 2024Stifel NicolausZentalis price target lowered to $10 from $32 at Stifel$10.00
Jun 18, 2024Morgan StanleyMorgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight$8.00
Jun 18, 2024JefferiesZentalis downgraded to Hold from Buy at Jefferies$6.00
May 7, 2024Stifel NicolausZentalis Pharmaceuticals (ZNTL) PT Lowered to $32 at Stifel$32.00
Nov 14, 2022WedbushWedbush Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $32$32.00
Nov 11, 2022GuggenheimGuggenheim Maintains Buy on Zentalis Pharmaceuticals, Lowers Price Target to $28$28.00
Nov 11, 2022Morgan StanleyMorgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Lowers Price Target to $55$55.00
Aug 10, 2022Leerink PartnersSVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $42$42.00